Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (XETRA:BRM) — Drug Manufacturers - General. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 6. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- bms.com
- Relations avec les Investisseurs
- bms.com/investors.html
- Secteur
- Healthcare · Drug Manufacturers - General
- Siège Social
- PRINCETON, United States
- PDG
- Christopher S. Boerner
- Employés
- 32 500
- Fondée
- 1989
- Actions en Circulation
- 2.04 Md au 2026-07-22
- Flottant
- 2.04 Md
- Capitalisation Boursière
- 128.41 Md USD
- Initiés
- 0.1%
- Investisseurs Institutionnels
- 84.87%
- Secteur d'Activité (SIC)
- Pharmaceutical Preparations
- Forme Juridique
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- P/E
- 13.8
- Taux de Distribution
- 54.9%
- FCF
- 11.4 Md USD
- Versements / FCF
- 45%
- Dette
- 43.9 Md USD3.1 ans de FCF
- Ancienneté du Dividende
- 54 ans
- Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
- NAV
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bourses et Tickers
| Bourse | Ticker | Devise | Prix | Type |
|---|---|---|---|---|
| US USA Stocks | BMY principale | USD | 60.57 +2.18% | actions ordinaires |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | actions ordinaires |
| MI Borsa Italiana (Milan) | 1BMY secondaire | EUR | 54.3 -1.08% | actions ordinaires |
| MX Mexican Stock Exchange | BMY secondaire | MXN | 1 130 +7.93% | actions ordinaires |
| VI Vienna Stock Exchange | BMYS secondaire | EUR | 52.98 +0.34% | actions ordinaires |
| XETRA Xetra | BRM secondaire | EUR | 53.04 +0.89% | actions ordinaires |
Dividendes
Bristol-Myers Squibb Company (BMY) verse des dividendes trimestriels. Par an (12 mois jusqu'au dernier paiement annoncé inclus) : 2.52 USD par action (paiements : 4). Cela représente environ 4.16% du cours actuel de l'action. D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 01.01.2027. Historique des dividendes ininterrompu : 54 ans.
| Date Ex | Versement | Montant | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-02 | 2026-11-02 | 0.6300 USD | 1.0/4.1 % | trimestriel | US:BMY |
| 2026-07-02 | 2026-08-03 | 0.6300 USD | 1.1/4.4 % | trimestriel | US:BMY |
| 2026-04-02 | 2026-05-01 | 0.6300 USD | 1.0/4.0 % | trimestriel | US:BMY |
| 2026-01-02 | 2026-02-02 | 0.6300 USD | 1.2/4.6 % | trimestriel | US:BMY |
| 2025-10-03 | 2025-11-03 | 0.6200 USD | 1.4/5.4 % | trimestriel | US:BMY |
| 2025-07-03 | 2025-08-01 | 0.6200 USD | 1.3/5.2 % | trimestriel | US:BMY |
| 2025-04-04 | 2025-05-01 | 0.6200 USD | 1.1/4.2 % | trimestriel | US:BMY |
| 2025-01-03 | 2025-02-03 | 0.6200 USD | 1.1/4.3 % | trimestriel | US:BMY |
| 2024-10-04 | 2024-11-01 | 0.6000 USD | 1.0/4.0 % | trimestriel | US:BMY |
| 2024-07-05 | 2024-08-01 | 0.6000 USD | 1.0/3.9 % | trimestriel | US:BMY |
| 2024-04-04 | 2024-05-01 | 0.6000 USD | 1.0/3.9 % | trimestriel | US:BMY |
| 2024-01-04 | 2024-02-01 | 0.6000 USD | 1.0/3.8 % | trimestriel | US:BMY |
| 2023-10-05 | 2023-11-01 | 0.5700 USD | 0.9/3.8 % | trimestriel | US:BMY |
| 2023-07-06 | 2023-08-01 | 0.5700 USD | 0.9/3.7 % | trimestriel | US:BMY |
| 2023-04-06 | 2023-05-01 | 0.5700 USD | 0.9/3.7 % | trimestriel | US:BMY |
| 2023-01-05 | 2023-02-01 | 0.5700 USD | 0.9/3.6 % | trimestriel | US:BMY |
| 2022-10-06 | 2022-11-01 | 0.5400 USD | 0.9/3.6 % | trimestriel | US:BMY |
| 2022-06-30 | 2022-08-01 | 0.5400 USD | 0.9/2.7 % | trimestriel | US:BMY |
| 2022-03-31 | 2022-05-02 | 0.5400 USD | 0.9/1.8 % | trimestriel | US:BMY |
| 2022-01-06 | 2022-02-01 | 0.5400 USD | 0.9/0.9 % | trimestriel | US:BMY |
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 M | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 M | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 M | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 M | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 M | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 M | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 M | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 M | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 M | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 M | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 M | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 M | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 M | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
